---
---

# 21 U.S.C., USLM ref /us/usc/t21/s353b

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s353a.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s354.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs353b)

## § 353b. Prereview of television advertisements

    (a) __In general__ 

        The Secretary may require the submission of any television advertisement for a drug (including any script, story board, rough, or a completed video production of the television advertisement) to the Secretary for review under this section not later than 45 days before dissemination of the television advertisement.

    (b) __Review__ 

    In conducting a review of a television advertisement under this section, the Secretary may make recommendations with respect to information included in the label of the drug—

        (1)

         on changes that are—

            (A) necessary to protect the consumer good and well-being; or

            (B) consistent with prescribing information for the product under review; and

        (2) if appropriate and if information exists, on statements for inclusion in the advertisement to address the specific efficacy of the drug as it relates to specific population groups, including elderly populations, children, and racial and ethnic minorities.

    (c) __No authority to require changes__ 

        Except as provided by subsection (e), this section does not authorize the Secretary to make or direct changes in any material submitted pursuant to subsection (a).

    (d) __Elderly populations, children, racially and ethnically diverse communities__ 

        In formulating recommendations under subsection (b), the Secretary shall take into consideration the impact of the advertised drug on elderly populations, children, and racially and ethnically diverse communities.

    (e) __Specific disclosures__ 

        (1) __Serious risk; safety protocol__ 

            In conducting a review of a television advertisement under this section, if the Secretary determines that the advertisement would be false or misleading without a specific disclosure about a serious risk listed in the labeling of the drug involved, the Secretary may require inclusion of such disclosure in the advertisement.

        (2) __Date of approval__ 

            In conducting a review of a television advertisement under this section, the Secretary may require the advertisement to include, for a period not to exceed 2 years from the date of the approval of the drug under [section 355 of this title][/us/usc/t21/s355] or [section 262 of title 42][/us/usc/t42/s262], a specific disclosure of such date of approval if the Secretary determines that the advertisement would otherwise be false or misleading.

    (f) __Rule of construction__ 

        Nothing in this section may be construed as having any effect on requirements under [section 352(n) of this title][/us/usc/t21/s352/n] or on the authority of the Secretary under section 314.550, 314.640, 601.45, or 601.94 of title 21, Code of Federal Regulations (or successor regulations).

([June 25, 1938, ch. 675, § 503B][/us/act/1938-06-25/ch675/s503B], as added [Pub. L. 110–85, title IX, § 901(d)(2)][/us/pl/110/85/s901/d/2], Sept. 27, 2007, [121 Stat. 939][/us/stat/121/939].)

 __Effective Date__ 

    Section effective 180 days after Sept. 27, 2007, see [section 909 of Pub. L. 110–85][/us/pl/110/85/s909], set out as an Effective Date of 2007 Amendment note under [section 331 of this title][/us/usc/t21/s331].

----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s353a.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s354.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs353b)

----------
----------

[/us/usc/t21/s355]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs355
[/us/usc/t42/s262]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs262
[/us/usc/t21/s352/n]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs352%2Fn
[/us/act/1938-06-25/ch675/s503B]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1938-06-25%2Fch675%2Fs503B
[/us/pl/110/85/s901/d/2]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F110%2F85%2Fs901%2Fd%2F2
[/us/stat/121/939]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F121%2F939
[/us/pl/110/85/s909]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F110%2F85%2Fs909
[/us/usc/t21/s331]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs331


